Abstract
Macrobiomolecular treatments for ocular inflammatory diseases have been described in a previous review. This article mainly discusses the application of small molecules in uveitis therapy, which includes corticosteroids, salicylic acid (aspirin), metabolite analogs, and anti-oxidative agents. Additionally, we update recent advances in peptide and nucleic acid related therapies, and focus mainly on the calcineurin inhibitor, cyclosporine, oral tolerant retinal proteins/peptides, gene therapy and ribonucleic acid interference strategies. We classify these immunomodulatory agents by their molecular signatures and highlight the molecular structure and mechanisms of function. These developments in understanding molecular mechanisms of the diseases, with the advent of new technologies, advance current therapeutic approaches. The future direction is to tailor treatments to individual patients in order to provide the safest and most effective therapies for ocular inflammatory diseases.
Keywords: Uveitis, macrobiomolecule, small molecule, immunosuppresion, anti-inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Application of Small Molecules/Macromolecules in Ocular Inflammatory Diseases
Volume: 11 Issue: 2
Author(s): Baoying Liu, Chi-Chao Chan and Robert B. Nussenblatt
Affiliation:
Keywords: Uveitis, macrobiomolecule, small molecule, immunosuppresion, anti-inflammation
Abstract: Macrobiomolecular treatments for ocular inflammatory diseases have been described in a previous review. This article mainly discusses the application of small molecules in uveitis therapy, which includes corticosteroids, salicylic acid (aspirin), metabolite analogs, and anti-oxidative agents. Additionally, we update recent advances in peptide and nucleic acid related therapies, and focus mainly on the calcineurin inhibitor, cyclosporine, oral tolerant retinal proteins/peptides, gene therapy and ribonucleic acid interference strategies. We classify these immunomodulatory agents by their molecular signatures and highlight the molecular structure and mechanisms of function. These developments in understanding molecular mechanisms of the diseases, with the advent of new technologies, advance current therapeutic approaches. The future direction is to tailor treatments to individual patients in order to provide the safest and most effective therapies for ocular inflammatory diseases.
Export Options
About this article
Cite this article as:
Liu Baoying, Chan Chi-Chao and B. Nussenblatt Robert, Application of Small Molecules/Macromolecules in Ocular Inflammatory Diseases, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2012; 11 (2) . https://dx.doi.org/10.2174/187152312803305713
DOI https://dx.doi.org/10.2174/187152312803305713 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair
Current Pharmaceutical Design Osteoclast Apoptosis in Rheumatic Diseases Characterized by a High Level of Bone Resorption (Osteoporosis, Rheumatoid Arthritis, Myeloma and Pagets Disease of Bone)
Current Rheumatology Reviews Morphological and Functional Characteristic of Senescent Cancer Cells
Current Drug Targets Presenilin and γ -Secretase Activity: A Viable Therapeutic Target for Alzheimers Disease?
Current Signal Transduction Therapy Primary Lung Lymphoma
Current Drug Targets - Inflammation & Allergy MicroRNAs in Human Diseases
Recent Patents on DNA & Gene Sequences Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer
Current Cancer Drug Targets Sources of β-Cells for Cell Therapy in Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Lentiviral Delivery of RNAi Effectors Against HIV-1
Current Topics in Medicinal Chemistry Pharmacogenetics of Asthma Therapy
Current Pharmaceutical Design Studies on Chloride Channels and their Modulators
Current Topics in Medicinal Chemistry EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Preclinical Models to Study Breast Cancer
Clinical Cancer Drugs Curious (Old and New) Antiviral Nucleoside Analogues with Intriguing Therapeutic Potential
Current Medicinal Chemistry Synthesis and Anticancer Activity of Some 2-[3/4-(2-Substituted Phenyl-2- oxoethoxy)benzylidene]-6-substituted-2,3-dihydro-1H-inden-1-one Derivatives
Letters in Drug Design & Discovery Biomedical Applications of Superparamagnetic Nanoparticles in Molecular Scale
Current Organic Chemistry BAFFling Autoimmune Disorders and Helicobacter pylori Disease: The Interplay between BAFF and the Th17 Response
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
Current Cancer Drug Targets Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers
Recent Patents on Anti-Cancer Drug Discovery Metabolic Response Assessment in Non-Small Cell Lung Cancer Patients after Platinum-Based Therapy: A Preliminary Analysis
Current Medical Imaging